# CS2/CS12 Study Design
Keywords: SMA, 5q SMA, Spinraza, clinical trial, HFMSE, 6MWT, SMN2, Phase II, open-label study

> This page provides detailed information about the CS2/CS12 clinical trial design for Spinraza, focusing on later-onset SMA (Type II and Type III), including patient demographics, study assessments, and trial outcomes.

## Details
- [Patient Population](#): Later-onset SMA (Type II and Type III) patients aged 2-15 years at first dose.
- [Study Type](#): Analysis across two open-label studies.
- [Median Age at First Dose](#): Patient age ranged from 2 to 15 years.
- [Trial Length](#): The study spanned 35 months, including a planned interim analysis.
- [Study Assessments](#): Evaluations included HFMSE and 6-Minute Walk Test (6MWT).
- [Number of SMN2 Copies](#): Distribution of SMN2 gene copies among patients: 4% with 2 copies, 75% with 3 copies, and 21% with 4 copies.